The Latest Updates From the Gene-Editing Clinical...
Feb. 26, 2025
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
PeterBio
Company Type: Therapeutic development
Main focus: Developing engineered gene- and cell therapies to treat genetic disorders
Company stage: Pre-clinical
Diseases: Metabolic disorders, sickle cell disease, duchenne muscular dystrophy and cancer
Genome-editing tool: Zinc finger nuclease coupled with a helicase beta-wing
Funding stage: Private
Location: Boston, Massachusetts, USA
Website: www.peterbio.com
Pipeline: www.peterbio.com/programs/
Partners:
PeterBio is a biotechnology company focused on the development of engineered gene- and cell therapies for the treatment of genetic disorders and cancer. The company’s proprietary gene-editing platform, RITDM™ (Recombination Induced Template-driven DNA Modification), uses a zinc finger array fused to a helicase beta-wing to introduce gene corrections to disease-causing mutations.
